17基因基因组前列腺评分检测可独立于PTEN状态预测根治性前列腺切除术后结局
OBJECTIVE: To compare the ability of loss of phosphatase and tensin homolog (PTEN) and Genomic prostate score assay (GPS) in predicting the biochemical-recurrence (BCR) and clinical-recurrence (CR) after radical prostatectomy (RP) for clinically localized prostate cancer (PCa).…
要点
- GPS可独立于PTEN状态预测根治性前列腺切除术后生化复发和临床复发。
- 校正GPS结果后,PTEN缺失对复发不再具有独立预测价值。
- PTEN状态与GPS结果仅弱相关,GPS在PTEN缺失病例中仍呈广泛分布。
核心结论
- GPS是侵袭性前列腺癌的显著预测因子,且独立于PTEN状态。
- 校正GPS结果后,PTEN缺失与前列腺癌复发无独立关联。
研究设计与样本
- 对根治性前列腺切除标本进行PTEN状态检测(免疫组化IHC和荧光原位杂交FISH)及GPS检测。
主要发现
- 队列基线平均年龄61.1岁,平均PSA 8 ng/dL,平均GPS评分32.8。
关键数值与推荐
- BCR定义为PSA≥0.2 ng/mL或因PSA升高启动挽救治疗。
- CR定义为局部复发和/或远处转移。
临床怎么用
- 在根治性前列腺切除术后风险评估中,GPS可提供独立于PTEN状态的预后信息。
- PTEN缺失的预后价值在纳入GPS后不再独立,临床解读复发风险时应优先参考GPS。
局限性
- 回顾性研究设计,采用分层队列抽样,可能存在选择偏倚。
- PTEN状态与GPS结果仅弱相关,GPS在PTEN缺失病例中仍广泛分布,提示前列腺癌生物学异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the ability of loss of phosphatase and tensin homolog (PTEN) and Genomic prostate score assay (GPS) in predicting the biochemical-recurrence (BCR) and clinical-recurrence (CR) after radical prostatectomy (RP) for clinically localized prostate cancer (PCa). METHODS: Three hundred seventy seven patients with and without CR were retrospectively selected by stratified cohort sampling design from RP database. PTEN status (by immunohistochemistry [IHC] and fluorescence in situ hybridization [FISH]) and GPS results were determined for RP specimens. BCR was defined as Prostate Specific Antigen (PSA) ≥ 0.2 ng/mL or initiation of salvage therapy for a rising PSA. CR was defined as local recurrence and/or distant metastases. RESULTS: Baseline mean age, PSA, and GPS score for the cohort were 61.1 years, 8 ng/dL, and 32.8. PTEN loss was noted in 38% patients by FISH and 25% by IHC. The concordance between FISH and IHC for PTEN loss was 66% (Kappa coefficient 0.278; P < .001). On univariable analysis, loss of PTEN by FISH or IHC was associated with BCR and CR (P < .05). However, after adjusting for GPS results, PTEN loss was not a significant predictor for CR or BCR (P > .1). The GPS result remained strongly associated with CR and BCR after adjusting for PTEN status (P < .001). PTEN status and GPS results only weakly correlated. GPS was widely distributed regardless of PTEN status indicating the biological heterogeneity of PCa even in PTEN-deficient cases. CONCLUSION: GPS is a significant predictor of aggressive PCa, independent of PTEN status. After adjustment for GPS results, PTEN was not independently associated with recurrence for PCa.
引用
- Magi-Galluzzi C, Isharwal S, Falzarano SM, et al. The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status. Urology. 2018. PMID: 30142405. doi:10.1016/j.urology.2018.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。